Kura tees up its lead drug with a 'breakthrough' at the FDA; NCI teams up with Cybrexa on peptide drug conjugate
Kura Oncology CEO Troy Wilson laid out some good news for investors this morning as he set the stage for their Q4 review.
The biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
